Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Fig. 3

Pharmacodynamic assessment of target coverage and T cell activation. a flow cytometry analysis of GITR expression among peripheral blood Tregs pretreatment and posttreatment. b immunohistochemistry assessment of GITR expression and T cell activation in tumor biopsies pretreatment and posttreatment. c immunohistochemistry evidence of immune modulation following treatment (cycle 3, day 43) versus screening in a colorectal cancer biopsy. aLines not visible for 7 patients due to lack of GITR+ cells at pretreatment

Back to article page